Cell Signaling Technology

Product Pathways - Neuroscience

SSTR1 Antibody #11830

Applications Reactivity Sensitivity MW (kDa) Source
W R (H) (M) (Mk) Endogenous 40, 80 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human  M=Mouse  R=Rat  Mk=Monkey
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

SSTR1 Antibody recognizes endogenous levels of total SSTR1 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val365 of human SSTR1 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from COS-7 cells, mock transfected (-) or transfected with a construct expressing human SSTR1 (hSSTR1; +), using SSTR1 Antibody. Multiple bands are thought to be GPCR dimers and/or oligomers (Rozenfeld, R. and Devi, L.A. (2010) Handbook of Cell Signaling, 2nd edition, 185-94). Smearing is thought to be due to the addition of N-linked glycosylations at specific NXS/T motifs (Dong, C. et al. (2007) Biochem Biophys Acta 1768, 853-70).

Western Blotting

Western Blotting

Western blot analysis of extract from PC-12 cells using SSTR1 Antibody.

Background

Somatostatin receptors are part of the super family of G protein-coupled receptors. Five genes encoding six different somatostatin receptor subtypes (SSTR1, SSTR2A, SSTR2B, SSTR3, SSTR4, and SSTR5) have been cloned (1). Somatostatin receptors are activated by somatostatin, a neuropeptide that acts as a neurotransmitter in the brain that regulates hormone secretion from endocrine tissues (2). Somatostatin receptors are found to be highly expressed on human neuroendocrine tumors (3).

mRNA expression data and immunohistochemical studies indicate high expression of SSTR1 in pituitary and gastroenteropancreatic tumor, renal, colorectal and breast cancer, meningioma, glioma neuroblastoma, and pheochromocytoma (3).

  1. Patel, Y.C. (1999) Front Neuroendocrinol 20, 157-98.
  2. Tulipano, G. and Schulz, S. (2007) Eur J Endocrinol 156 Suppl 1, S3-11.
  3. Hofland, L.J. and Lamberts, S.W. (2003) Endocr Rev 24, 28-47.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products